INOVIQ Ltd (ASX:IIQ)

Australia · Delayed Price · Currency is AUD

0.1750

+0.0100 (6.06%)

Aug 27, 2026, 3:59 PM AEST

-56.25% (1Y)

Market Cap	24.64M -44.8%
Revenue (ttm)	2.61M +17.4%
Net Income	-7.51M
EPS	-0.06
Shares Out	140.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	154,818
Open	0.1700
Previous Close	0.1650
Day's Range	0.1700 - 0.1750
52-Week Range	0.1650 - 0.5650
Beta	1.55
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 3, 2026

About INOVIQ

INOVIQ Ltd develops and commercializes diagnostic and exosome‐based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of can... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 2016

Employees 15

Stock Exchange Australian Securities Exchange

Ticker Symbol IIQ

Full Company Profile

Financial Performance

In fiscal year 2026, INOVIQ's revenue was 2.61 million, an increase of 44.01% compared to the previous year's 1.82 million. Losses were -7.51 million, 8.26% more than in 2025.

Financial Statements